Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Mirtazapine D3 (6-Azamianserin D3; Org-3770 D3) is the tri-deuterated form of Mirtazapine (Remeron), which is is an orally bioactive atypical antidepressant acting as a 5-HT2/3 receptor inhibitor as well as an noradrenergic and specific serotonergic antidepressant (NaSSA) agent.
ln Vivo |
The phenotypic scores of MeCP2-null mice were improved by mirtazapine (ip; 10–50 mg/Kg; 14 days) treatment, which also normalized heart rate, respiratory rate, anxiety levels, and eliminated the jumping behavior [ 2].
|
---|---|
Animal Protocol |
Animal/Disease Models: MeCP2-deficient mice [2]
Doses: 10-50 mg/Kg Route of Administration: intraperitoneal (ip) injection; 10-50 mg/kg; 14 days Experimental Results: The thickness of the somatosensory cortex of MeCP2-deficient mice was restored, especially II -Layer III and VI. |
References |
[1]. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64.
[2]. Kooyman AR, et al. Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells.Neuropharmacology. 1994 Mar-Apr;33(3-4):501-7. |
Molecular Formula |
C₁₇H₁₆D₃N₃
|
---|---|
Molecular Weight |
268.37
|
CAS # |
1216678-68-0
|
Related CAS # |
Mirtazapine;85650-52-8;(S)-Mirtazapine;61337-87-9;(S)-Mirtazapine-d3;(R)-Mirtazapine;61364-37-2;(R)-Mirtazapine-d3
|
SMILES |
C([2H])([2H])([2H])N1CCN2C3=NC=CC=C3CC3=CC=CC=C3C2C1
|
Synonyms |
Org 3770 D3 Org3770 D3 Mirtazapine D3 6-Azamianserin D3Org-3770 D3
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~372.62 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.7262 mL | 18.6310 mL | 37.2620 mL | |
5 mM | 0.7452 mL | 3.7262 mL | 7.4524 mL | |
10 mM | 0.3726 mL | 1.8631 mL | 3.7262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.